DiaMedica Therapeutics Inc

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DiaMedica Therapeutics addresses FDA concerns amidst financial stability

DiaMedica Therapeutics maintains a strong financial position, but faces challenges with the clinical hold on their pivotal trial, requiring proactive resolution.
Despite increased expenses, the company's commitment to addressing regulatory feedback and ensuring patient safety presents growth opportunities in the long term.
Resolving the clinical hold swiftly and resuming trial enrollment are key priorities for DiaMedica to advance their clinical programs and unlock future potential.

DiaMedica progresses on FDA concerns with stable finances and new leadership

DiaMedica Therapeutics is actively addressing FDA concerns on DM199, supported by a stable financial position and a strengthened management team.
While facing challenges in meeting regulatory requirements and managing increased expenses, DiaMedica sees opportunities in resolving adverse events and advancing DM199.
Overall, DiaMedica's progress, financial stability, and strategic additions position the company well for potential FDA approval and further development of DM199.

DiaMedica Therapeutics reports strong Q2 performance and eyes global expansion

DiaMedica Therapeutics made significant progress in Q2 2023, achieving key milestones, strengthening financial position, and advancing product development.
While facing challenges in patient enrollment and legal matters, the company is well-positioned to capitalize on opportunities for global expansion and market growth.
Overall, DiaMedica's focus on efficient treatment delivery and commitment to innovation position them for future success in the biopharmaceutical industry.

DiaMedica reports solid Q3 results amidst strategic protocol enhancements

DiaMedica Therapeutics showcased robust financials in Q3 2023, driven by successful private placements and strategic cost management.
The appointment of Dr. Ambar Shah and protocol enhancements for ReMEDy2 reflect a commitment to innovation and clinical advancement.
However, challenges persist with patient enrollment, protocol adjustments, and legal proceedings, necessitating focused efforts to mitigate risks and drive progress.

DiaMedica Therapeutics reports robust 2023 performance and advances stroke treatment

DiaMedica Therapeutics' strong financial performance and progress in the ReMEDy2 trial highlight the company's growth potential.
Appointment of a new Chief Medical Officer and protocol revisions demonstrate a commitment to advancing clinical development efforts.
While facing challenges in site commitments and trial complexities, the company has opportunities for global expansion and market penetration.

DiaMedica reports robust Q1 earnings, eyes trial expansion opportunities

DiaMedica Therapeutics showcased strong financial performance and positive trial progress in Q1 2024.
While facing challenges such as increased operating expenses and a legal appeal, the company remains well-positioned for growth.
Opportunities lie in expanding trials, leveraging the success in China, and building a robust foundation for future drug development.

DiaMedica Therapeutics progresses on key programs amidst financial stability

DiaMedica Therapeutics is on track for a transformative 2025 with progress on key programs and enrollment enhancements.
Strategic protocol updates and financial stability bolster the company's position for future growth and clinical success.
Challenges around protocol changes and enrollment optimization require careful navigation for sustained progress.
Opportunities lie in protocol enhancements, regulatory milestones, and financial strength to drive innovation and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal diseases, today announced positive interim results from its Phase 2 REDUX trial of DM199 in chronic kidney disease (CKD). The REDUX trial is studying the treatment of CKD in three populations with rare or high unmet medical needs: African Americans (AA), non-diabetic and hypertensive (Cohort 1, n=1

DiaMedica Therapeutics Announces Positive Interim Results from Phase 2 REDUX Study in CKD

DiaMedica produced decent stroke data last year for DM199. The company does not have a lot of cash.

DiaMedica: Undercovered Stroke Drug Company With Decent Data

Investors need to pay close attention to DiaMedica (DMAC) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in DiaMedica (DMAC) Stock?

The FDA has signed off DiaMedica Therapeutics Inc's (NASDAQ: DMAC) Investigational New Drug (IND) application to proceed with a pivotal Phase 2/3 study of DM199 (recombinant human tissue kallikrein-1or KLK1) for the treatment of patients with Acute Ischemic Stroke (AIS). The upcoming pivotal ReMEDy2 trial will evaluate whether DM199 can improve three-month outcomes in AIS patients without other treatment options.

DiaMedica Stock Gains On Green Signal To Start Pivotal DM199 Trial In Ischemic Stroke

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical Company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S. Food & Drug Administration (FDA) has accepted the Company's Investigational New Drug (IND) application. The Company plans to proceed with a pivotal Phase 2/3 study of DM199 (recombinant human tissue kallikrein-1or KLK1) for the treatment of patients with Acute

DiaMedica Therapeutics Announces FDA Clearance of IND Application to Initiate Phase 2/3 Clinical Trial for DM199 for Acute Ischemic Stroke

DiaMedica Therapeutics Inc.'s (DMAC) CEO Rick Pauls on Q1 2021 Results - Earnings Call Transcript

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the quarter ended March 31, 2021. DiaMedica will host a conference call Thursday, May 6, 2021, at 7:00 a.m. Central Time to discuss its business update and first quarter financial results. Clinical Developments DM199 for the Treatment o

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2021 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first quarter 2021 financial results will be released after the markets close on Wednesday, May 5th. DiaMedica will host a live conference call on Thursday, May 6th at 7:00 AM Central Time to discuss its business update and financial results. Conference Call details: Da

DiaMedica Therapeutics to Report First Quarter 2021 Financials and Provide a Business Update May 6, 2021

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Rick Pauls, President and CEO, will deliver a corporate presentation at B. Riley's Neuroscience Investor Conference on Thursday, April 29th at 11:30am ET. DiaMedica will be available for one-on-one meetings at this conference and investors may request a one-on-one meeti

DiaMedica Therapeutics to Participate in the B. Riley Securities' Neuroscience Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the National Kidney Foundation (NKF) 2021 Spring Clinical Meetings (SCM21) being held virtually from April 6 – 10, 2021. For information about the virtual event, visit: https://www.kidney.org/spring-clinical. The DiaMedica abs

DiaMedica Therapeutics to Present Research at the National Kidney Foundation's 2021 Spring Clinical Meetings

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2020 Results - Earnings Call Transcript

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the year ended December 31, 2020. DiaMedica will host a conference call Thursday, March 11, 2021, at 7:00 a.m. Central Time to discuss its business update and full year financial results. Clinical Developments DM199 for the Treatment of

DiaMedica Therapeutics Announces 2020 Financial Results and Provides a Business Update

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel recombinant proteins in the treatments for neurological and kidney diseases, today announced it will be presenting a plenary talk at the American Heart Association 2021 International Stroke Conference titled “Safety and Tolerability of Recombinant Human Tissue Kallikrein (DM199) In Acute Ischemic Stroke: A Randomized Clinical Trial”. The International Stroke Conf

DiaMedica Therapeutics to Present Research at International Stroke Virtual Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will host a key opinion leader (KOL) webinar on DM199, the Company's lead asset for the treatment of Acute Ischemic Stroke (AIS), on Friday, March 19, 2021 at 12:00pm Eastern Time. The webinar will feature presentations by KOLs Scott Kasner, M.D., University of Pennsylvania, and Paolo Madedd

DiaMedica Therapeutics Hosting Key Opinion Leader Webinar on DM199 for Treatment of Acute Ischemic Stroke

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its fourth quarter 2020 financial results will be released after the markets close on Wednesday, March 10th. DiaMedica will host a live conference call on Thursday, March 11th at 7:00 AM Central Time to discuss its business update and financial results. Conference Call deta

DiaMedica Therapeutics to Report Fourth Quarter 2020 Financials and Provide a Business Update March 11, 2021

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that Dr. Harry Alcorn, its Chief Medical Officer will be presenting “CKD DM199 Research Update” at the 3rd Chronic Kidney Disease Drug Development (“CKD3”) summit virtually on Tuesday March 2nd, 2021, at 1:00pm Eastern Time. The presentation will include data from the CKD Phase 1b study and an overv

DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting

Bausch Health Companies Inc

iBio

Oncolytics Biotech, Inc.

Outlook Therapeutics Inc

iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates.

Why Bausch Health, Oncolytics Biotech, And More Are Moving Today

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021. The recorded presentation will be available on the Investors section of the Company's website at https://ir.diamedica.com/events-and-presentations beginning Monday, January

DiaMedica Therapeutics to Present at the H.C. Wainwright BioConnect Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that the last participant has been enrolled and is on treatment in the diabetic kidney disease Cohort of the Company's Phase 2 REDUX chronic kidney disease (CKD) study. The Company also announced that enrollment has reached 50% in the IgA Nephropathy and African Americans cohorts. DiaMedica's Phase 2 REDUX (Latin for restore) study is a multi-center, open-label, investigation to assess the safety and effica

DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that it recently received written responses from the FDA following a Type B Pre-IND meeting request that the Company submitted in October 2020 regarding the Company's development plan for its product candidate, DM199, in the treatment of acute ischemic stroke (AIS). DiaMedica believes that the feedback received from the FDA provides a well-defined regulatory pathway and plans to immediately proceed with preparing

DiaMedica Therapeutics Announces Successful Type B Meeting with FDA for the Study of DM199 in Patients with Acute Ischemic Stroke

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders, is pleased to announce that Rick Pauls, President and CEO of DiaMedica, will participate in a fireside chat and host one-on-one meetings with investors at the Piper Sandler 32nd Annual Virtual Growth Conference. The fireside chat will be available on the Piper Sandler Conference website

DiaMedica Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for chronic kidney diseases and neurological disorders, today announced its President and CEO, Rick Pauls, and Chief Financial Officer, Scott Kellen, are scheduled to participate in the Craig-Hallum Alpha Select Conference, which is being held as a virtual event on November 17, 2020. Meetings will take place virtually on November 17, 2020 given the ong

DiaMedica Therapeutics to Participate in 11th Annual Craig-Hallum Alpha Select Conference

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2020 Results - Earnings Call Transcript

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today provided a business update and financial results for the three and nine months ended September 30, 2020. DiaMedica will host a conference call tomorrow, November 5, 2020, at 7:00 a.m. Central Time to discuss its business update and third quarter financial results. Clinical Developments DM

DiaMedica Provides a Business Update and Third Quarter 2020 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its third quarter 2020 financial results will be released after the markets close on Wednesday, November 4th. DiaMedica will host a live conference call on Thursday, November 5th at 7:00 AM Central Time to discuss its business update and financial results. Conference Call details: Date: Thursday, November 5, 2020 Time: 7:00 AM CT / 8:00 AM ET Web access: https://event.on24.com/wcc/r/2623032/5A77F532891

News for DiaMedica Therapeutics Inc Stock (DMAC)